CHRISTOPHER W. CAIN - 04 Jun 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role
Director
Signature
/s/ Evan D. Kearns, Attorney-in-Fact
Issuer symbol
COGT
Transactions as of
04 Jun 2025
Transactions value $
$0
Form type
4
Filing time
05 Jun 2025, 16:24:15 UTC
Previous filing
01 May 2025
Next filing
02 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CAIN CHRISTOPHER W. Director C/O COGENT BIOSCIENCES, INC., 275 WYMAN STREET, 3RD FLOOR, WALTHAM /s/ Evan D. Kearns, Attorney-in-Fact 05 Jun 2025 0001817733

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COGT Stock Option (Right to Buy) Award $0 +44.7K $0.00 44.7K 04 Jun 2025 Common Stock 44.7K $5.64 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders.
F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.